Contraception for midlife women : a review
Family planning represents a key component of reproductive health care. Accordingly, the provision of contraception must span the reproductive age spectrum, including perimenopause. The risk of pregnancy is decreased, but not trivial, among women over 40 years of age. Evidence-based guidelines for contraceptive use can assist clinicians in counseling their patients in this population. Intrauterine contraception is one of the most effective methods and is safe to use in midlife women with few exceptions. Progestin-only contraception is another safe option for most midlife women because it is not associated with an increased risk of cardiovascular complications. Combined (estrogen-containing) contraception can be safely used by midlife women who do not have cardiovascular risk factors. Unique noncontraceptive benefits for this population include: improvement in abnormal uterine bleeding, decreased hot flashes, and decreased cancer risk. Finally, guidelines state that contraception can be used by midlife women without medical contraindications until the age of menopause, at which time they may consider transition to systemic hormone therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Menopause (New York, N.Y.) - 25(2018), 7 vom: 01. Juli, Seite 817-827 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Miller, Taniqua A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 13.09.2019 Date Revised 13.09.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/GME.0000000000001073 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM281205205 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM281205205 | ||
| 003 | DE-627 | ||
| 005 | 20231225031109.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/GME.0000000000001073 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0937.xml |
| 035 | |a (DE-627)NLM281205205 | ||
| 035 | |a (NLM)29462093 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Miller, Taniqua A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Contraception for midlife women |b a review |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.09.2019 | ||
| 500 | |a Date Revised 13.09.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Family planning represents a key component of reproductive health care. Accordingly, the provision of contraception must span the reproductive age spectrum, including perimenopause. The risk of pregnancy is decreased, but not trivial, among women over 40 years of age. Evidence-based guidelines for contraceptive use can assist clinicians in counseling their patients in this population. Intrauterine contraception is one of the most effective methods and is safe to use in midlife women with few exceptions. Progestin-only contraception is another safe option for most midlife women because it is not associated with an increased risk of cardiovascular complications. Combined (estrogen-containing) contraception can be safely used by midlife women who do not have cardiovascular risk factors. Unique noncontraceptive benefits for this population include: improvement in abnormal uterine bleeding, decreased hot flashes, and decreased cancer risk. Finally, guidelines state that contraception can be used by midlife women without medical contraindications until the age of menopause, at which time they may consider transition to systemic hormone therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Allen, Rebecca H |e verfasserin |4 aut | |
| 700 | 1 | |a Kaunitz, Andrew M |e verfasserin |4 aut | |
| 700 | 1 | |a Cwiak, Carrie A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Menopause (New York, N.Y.) |d 1998 |g 25(2018), 7 vom: 01. Juli, Seite 817-827 |w (DE-627)NLM093767102 |x 1530-0374 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2018 |g number:7 |g day:01 |g month:07 |g pages:817-827 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/GME.0000000000001073 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2018 |e 7 |b 01 |c 07 |h 817-827 | ||